康柏西普治疗中心性浆液性脉络膜视网膜病变:基于EDI-OCT的疗效观察

目的　应用深层光学相干断层成像（enhanced depth imaging-OCT，EDI-OCT）技术观察康柏西普治疗中心性浆液性脉络膜视网膜病变的疗效和安全性。方法　收集2015年7月至2017年7月在我院确诊的42例（44眼）中心性浆液性脉络膜视网膜病变的患者，在无菌条件下接受康柏西普（0.5 mg，0.05 mL）玻璃体内注射1次，分别于注药前及注药后1周、4周、12周记录最佳矫正视力；同时采用EDI-OCT测量不同时间点的黄斑中心凹下脉络膜厚度。结果　CSC患眼治疗后1周、4周、12周BCVA分别为0.57±0.23、0.62±0.23、0.59±0.71，均较治疗前的0.43±1.11明显提高，差异均有统计学意义（均为P＜0.05）。治疗后1周、4周、12周黄斑中心凹下脉络膜厚度分别为（308.17±16.52）μm、（286.54±37.52）μm、（274.58±41.38）μm，均较治疗前的（346.31±59.43）μm明显降低，差异均有统计学意义（均为P＜0.05）。结论　玻璃体内注射康柏西普治疗中心性浆液性脉络膜视网膜病变安全有效。

Efficacy of conbercept in the treatment of central serous choroidal retinopathy by EDI-OCT

Objective　To observe the efficacy and safety of conbercept in the treatment of central serous chorioretinopathy （CSC） by EDI-OCT.Methods　From July 2015 to July 2017，42 patients （44 eyes） of central serous choriodal retinopathy received intravitreal injection of conbercept （0.5 mg，0.05 mL）.Then，the best corrected visual acuity was recorded before injection and 1 week，4 weeks and 12 weeks after treatment；meanwhile，EDI-OCT was used to measure subfoveal choroidal thickness at different time points.Results　In CSC patients，the BCVA of 1 week，4 weeks and 12 weeks after treatment were 0.57±0.23，0.62±0.23 and 0.59±0.71，respectively，which were significantly higher than those before treatment ［（0.43±1.11）］（all P<0.05）.The subfoveal choroidal thickness was （308.17±16.52）μm，（286.54±37.52）μm and （274.58±41.38）μm at 1 week，4 weeks and 12 weeks after treatment，respectively，which were significantly lower than those before treatment ［（346.31±59.43）μm］ （all P<0.05）.Conclusion　It is safe and effective for conbercept injection in the treatment of CSC.